Biomarkers /

ZFP36L1

Back to Biomarkers List

Overview

Location [1]
14q24.1
Protein [2]
mRNA decay activator protein ZFP36L1
Synonyms [1]
Berg36, cMG1, ERF1, BRF1, ERF-1, TIS11B, RNF162B

ZFP36L1 is altered in 0.11% of all cancers with breast invasive ductal carcinoma, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and pancreatic adenocarcinoma having the greatest prevalence of alterations [3].

ZFP36L1 GENIE Cases - Top Diseases

The most common alterations in ZFP36L1 are ZFP36L1 Amplification (0.29%), ZFP36L1-IGH Fusion (0.02%), ZFP36L1 Fusion (0.01%), ZFP36L1 G270E (0.04%), and ZFP36L1 G270R (0.04%) [3].

ZFP36L1 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.